<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169906</url>
  </required_header>
  <id_info>
    <org_study_id>TS142-102</org_study_id>
    <nct_id>NCT04169906</nct_id>
  </id_info>
  <brief_title>A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)</brief_title>
  <official_title>A Phase I Study of TS-142 in Non-Elderly Healthy Participants (Repeated Doses) (A Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TS-142 in Non-Elderly Participants)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, pharmacokinetics, and
      pharmacodynamics of repeated dosing of TS-142 when administered once daily to healthy
      Japanese non-elderly participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 6, 2016</start_date>
  <completion_date type="Actual">October 8, 2016</completion_date>
  <primary_completion_date type="Actual">October 8, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs)</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>Number of Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) reported as mild, moderate, severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve AUC (tau)</measure>
    <time_frame>Day 1 up to Day 9</time_frame>
    <description>Concentration of TS-142 and its metabolites in plasma</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TS-142 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TS-142 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TS-142 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo once daily for 7 consective days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TS-142 10 mg</arm_group_label>
    <arm_group_label>TS-142 20 mg</arm_group_label>
    <arm_group_label>TS-142 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-142, 10 mg</intervention_name>
    <description>Participants will receive 10 mg of TS-142 once daily for 7 consective days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TS-142 10 mg</arm_group_label>
    <arm_group_label>TS-142 20 mg</arm_group_label>
    <arm_group_label>TS-142 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-142, 20 mg</intervention_name>
    <description>Participants will receive 20 mg of TS-142 once daily for 7 consective days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TS-142 10 mg</arm_group_label>
    <arm_group_label>TS-142 20 mg</arm_group_label>
    <arm_group_label>TS-142 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-142, 30 mg</intervention_name>
    <description>Participants will receive 30 mg of TS-142 once daily for 7 consective days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TS-142 10 mg</arm_group_label>
    <arm_group_label>TS-142 20 mg</arm_group_label>
    <arm_group_label>TS-142 30 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) â‰¥18.5 and &lt;25.0 kg/m^2 at screening inspection

        Exclusion Criteria:

          -  History of clinically relevant disease of some organ systems that may be considerd
             inappropriately for this study

          -  History of drug and food allergy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigeru Okuyama</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The medical facility selected by Taisho Pharmaceutical Co., Ltd</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

